Clinical Trial Update: Open-label Extension Study in Participants With Early Alzheimer's Disease [Phase 2]

View source ↗

Summary

This document details an open-label extension study (Phase 2) for participants with early Alzheimer's disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: RECRUITING